Welcome to our dedicated page for Viridian Therapeutics SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viridian Therapeutics, Inc. filings document a clinical-stage biotechnology company with common stock listed on Nasdaq under VRDN. The company’s Form 8-K disclosures report financial results, Regulation FD clinical updates, corporate presentations, and material agreements, including underwriting arrangements for common stock offerings.
Viridian’s regulatory filings also cover its thyroid eye disease programs, including elegrobart trial disclosures and updates related to veligrotug, as well as cash resources, research and development activity, and financing transactions. Proxy materials document annual meeting matters, director elections, executive compensation, equity plans, and related governance procedures.
Viridian Therapeutics (VRDN) announced an underwritten public offering of common stock. The company agreed to sell 11,425,000 shares at $22.00 per share, for aggregate gross proceeds of approximately $251.35 million before underwriting discounts, commissions, and expenses. Underwriters have a 30‑day option to purchase up to an additional 1,713,750 shares on the same terms. The offering was made under an automatically effective shelf registration statement and is expected to close on October 23, 2025.
Viridian states that the net proceeds, together with existing cash and other expected sources— including a $70 million upfront payment receivable from Kissei in the fourth quarter of 2025, the $55 million upfront payment from a purchase and sale agreement with DRI plus $115 million in potential near‑term milestones under that agreement, and $30 million from a term loan facility—should provide sufficient capital to fund currently anticipated operations. The company also references anticipated revenue from veligrotug and VRDN‑003 sales if each is approved on its anticipated timelines.
Viridian Therapeutics launched a primary offering of 11,425,000 shares of common stock at $22.00 per share. The deal implies a $251,350,000 gross raise, with underwriting fees of $15,081,000, for estimated net proceeds of $236,269,000 before expenses. Underwriters have a 30‑day option to purchase up to 1,713,750 additional shares.
The company plans to use proceeds, together with existing liquidity, to fund commercial launch activities for veligrotug and VRDN‑003, R&D, and for working capital and general corporate purposes.
Viridian noted preliminary cash, cash equivalents and marketable securities of $490.9 million as of September 30, 2025. Recent financing activities include a purchase and sale agreement with DRI providing up to $300 million in consideration, including $55 million received at signing, and an amended Hercules term loan facility of up to $300.0 million.
Nazdaq symbol: VRDN; settlement is expected on or about October 23, 2025.
Viridian Therapeutics (VRDN) launched a preliminary 424B5 for a primary offering of common stock and, in lieu of common for certain investors, Series B non-voting convertible preferred stock. Each Series B share converts into 66.67 shares of common at the holder’s election, subject to a holder‑set Beneficial Ownership Limitation between 4.9% and 19.9%. The company granted underwriters a 30‑day option to buy additional common shares. Net proceeds will support commercial launch activities for veligrotug and VRDN‑003, research and development, and general corporate purposes.
Viridian reported preliminary cash, cash equivalents and marketable securities of $490.9 million as of September 30, 2025. On October 17, 2025, it entered a Purchase and Sale Agreement with DRI for up to $300 million tied to clinical, regulatory and commercial milestones, with tiered U.S. net sales royalties of 7.5% up to $600 million, 0.8% from $600–$900 million, and 0.25% from $900 million–$2 billion. The same day, Viridian amended its Hercules facility to provide up to $300.0 million across tranches, maturing on October 17, 2030, with a floating rate capped at 9.45% and an interest‑only period through October 17, 2029 (extendable upon milestones). Common stock trades on Nasdaq as “VRDN”; Series B has no planned listing.
Viridian Therapeutics (VRDN) launched a preliminary 424B5 for a primary offering of common stock and, in lieu of common for certain investors, Series B non-voting convertible preferred stock. Each Series B share converts into 66.67 shares of common at the holder’s election, subject to a holder‑set Beneficial Ownership Limitation between 4.9% and 19.9%. The company granted underwriters a 30‑day option to buy additional common shares. Net proceeds will support commercial launch activities for veligrotug and VRDN‑003, research and development, and general corporate purposes.
Viridian reported preliminary cash, cash equivalents and marketable securities of $490.9 million as of September 30, 2025. On October 17, 2025, it entered a Purchase and Sale Agreement with DRI for up to $300 million tied to clinical, regulatory and commercial milestones, with tiered U.S. net sales royalties of 7.5% up to $600 million, 0.8% from $600–$900 million, and 0.25% from $900 million–$2 billion. The same day, Viridian amended its Hercules facility to provide up to $300.0 million across tranches, maturing on October 17, 2030, with a floating rate capped at 9.45% and an interest‑only period through October 17, 2029 (extendable upon milestones). Common stock trades on Nasdaq as “VRDN”; Series B has no planned listing.
Viridian Therapeutics (VRDN) announced a preliminary balance of approximately $490.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The figure is unaudited and subject to completion of financial closing procedures, and the company’s independent auditor has not performed any review or assurance work on this number. The final amount reported in the upcoming unaudited condensed consolidated balance sheet may differ materially.
Viridian Therapeutics (VRDN) announced a preliminary balance of approximately $490.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The figure is unaudited and subject to completion of financial closing procedures, and the company’s independent auditor has not performed any review or assurance work on this number. The final amount reported in the upcoming unaudited condensed consolidated balance sheet may differ materially.
Viridian Therapeutics, Inc. files an S-3ASR prospectus supplement describing its pipeline and offering mechanics. The company highlights lead programs including veligrotug (an intravenous anti-IGF-1R monoclonal antibody) and VRDN-003 (a planned low-volume, subcutaneous anti-IGF-1R intended for at-home auto-injector use for TED). The filing states VRDN-006 and VRDN-008 are engineered FcRn inhibitors. Stated timelines include VRDN-006 proof-of-concept IgG reduction data in Q3 2025, an anticipated IND submission for VRDN-008 by end of 2025, and anticipated VRDN-003 topline REVEAL-1 and REVEAL-2 data in H1 2026. As of September 3, 2025 the company had 81,668,033 common shares outstanding, 134,864 Series A and 145,160 Series B preferred shares. Use of proceeds is for development, commercialization preparation, working capital and general corporate purposes. The Registration Rights Agreement requires Viridian to use commercially reasonable efforts to register certain shares and explicitly does not include demand or piggyback registration rights.
Viridian Therapeutics (VRDN) filed an 8-K to disclose a collaboration and license agreement signed 30 Jul 2025 with Japan-based Kissei Pharmaceutical covering two IGF-1R monoclonal antibodies, veligrotug and VRDN-003, for thyroid eye disease and other potential indications in Japan. Kissei receives exclusive Japanese development and commercialization rights and a limited non-exclusive manufacturing right; Viridian retains global rights elsewhere and will supply product.
Financial terms: Kissei will pay $70 million upfront. Viridian is eligible for up to $315 million in development, regulatory and sales milestones. Tiered royalties in the low-20% to mid-30% range on future Japanese sales will follow launch. Kissei funds Japanese clinical, regulatory and commercial activities under joint-steering oversight, reducing Viridian’s cash burden.
Strategic impact: The agreement delivers immediate, non-dilutive capital, extends cash runway and externally validates VRDN-003/veligrotug while preserving all ex-Japan upside. Key execution risks include dependence on Kissei’s development success and Viridian’s ongoing manufacturing obligations.